Repligen Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial statements are unaudited. Repligen develops and sells technologies used in biopharmaceutical manufacturing.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $151.3 million | $182.7 million; down 17.1% |
| Gross margin | 49.5% | 55.2% |
| Income from operations | $2.0 million | $31.3 million |
| Net income | $2.1 million | $28.8 million |
| Diluted EPS | $0.04 | $0.51 |
| Cash from operating activities | $44.7 million | $11.2 million |
| Cash and cash equivalents | $780.6 million | $751.3 million at Dec. 31, 2023 |
| Working capital | $954.7 million | $952.9 million at Dec. 31, 2023 |
| Convertible notes, carrying value | $69.5 million due 2024; $513.9 million due 2028 | — |
Operating cash flow benefited from lower receivables and inventory, as well as changes in accrued expenses and lease liabilities. Capital expenditures were $8.3 million. The 2024 notes mature July 15, 2024; the 2028 notes bear 1.00% interest and mature December 15, 2028. Repligen said existing cash was sufficient for at least 24 months from the filing date, absent acquisitions of additional products, candidates or intellectual property.
Material changes and management commentary
- Product revenue fell $31.3 million year over year. Management attributed the decline mainly to lower COVID-19-related filtration demand as customers worked through inventory, and weakness in the proteins franchise, including Cytiva producing product in-house and lower ligand forecasts. FlexBiosys and Metenova acquisition revenue partially offset the declines.
- Gross margin decreased 5.7 percentage points, reflecting lower sales and production volumes and a mix shift away from higher-margin consumables. Cost of goods sold declined 6.7%, while SG&A rose 9.8%, partly due to acquisitions, higher employee costs and restructuring charges.
- Investment income increased to $9.0 million from $5.5 million. Interest expense rose to $4.9 million, largely reflecting the 2028 notes and amortization of their debt discount. Foreign currency-related other expenses were $3.5 million.
- The income tax provision was $20,000 and the effective tax rate was 0.9%, versus 20.1% in Q1 2023. Management cited lower pretax income and stock-related tax benefits.
Outlook, risks and unusual items
- No specific revenue or earnings guidance for 2024 is stated in the provided filing text. Management expects operating expenses to increase as the business expands and plans continued investment in product development, R&D and commercial capabilities.
- The restructuring plan, begun in 2023, includes manufacturing consolidation, discontinuation of certain product SKUs and review of pandemic-period inventory. Q1 2024 charges were $1.4 million; management expects completion by the end of Q3 2024.
- A New Jersey property was classified as held for sale at $1.0 million; the company aims to complete a sale within one year.
- Management reported disclosure controls were not effective at quarter-end because of an unremediated material weakness in controls over deferred-tax accounting for complex, non-routine transactions, including the convertible-note exchange and issuance. Remediation is underway; the weakness is not considered resolved until controls have operated effectively for a sufficient period and have been tested.
- Macroeconomic and business risks include currency fluctuations, inflation and supply costs, lower COVID-related demand, customer purchasing patterns, acquisition integration and competition. The filing reports no material change to previously disclosed risk factors and no known legal proceedings expected to have a material adverse effect.
Important facts for investors to verify
- Whether demand weakness in COVID-related products and the proteins franchise persists, and how acquisition contributions affect growth.
- Progress in restoring gross margin and controlling SG&A as restructuring and acquisition-related costs evolve.
- Settlement or conversion of the $69.6 million principal amount of 2024 notes ahead of their July 2024 maturity, and the potential effect of the 2028 notes.
- Completion of the restructuring plan and the planned sale of the BioFlex property.
- Remediation and testing of the material weakness in financial reporting controls, including changes associated with the ERP rollout.
- Finalization of Metenova purchase accounting and the timing and amount of acquisition earnout payments.